BullFrog AI Holdings, Inc. (NASDAQ: BFRG) is a technology-driven biopharmaceutical company founded in 2017 and headquartered in Gaithersburg, Maryland. The company leverages artificial intelligence (AI) and machine learning (ML) to enhance drug development processes, aiming to improve clinical outcomes and reduce the reliance on trial-and-error treatment strategies. Its mission is to identify critical connections between therapies and responsive patient populations efficiently and precisely.
Key Strategic Focus
BullFrog AI's strategic focus centers on integrating advanced AI/ML analytics into the drug development pipeline. The company's proprietary bfLEAP™ platform analyzes complex biological, clinical, and real-world data to identify therapeutic targets and opportunities for drug repurposing. This approach aims to streamline data analytics in therapeutics development, decrease overall development costs by reducing failure rates for new therapeutics, and impact the lives of patients who may have otherwise not received the therapies they need.
Financials and Funding
BullFrog AI completed its initial public offering (IPO) on February 14, 2023, raising approximately $8.4 million through the sale of 1,297,318 units at $6.50 per unit. Each unit comprised one share of common stock and accompanying warrants. As of July 21, 2025, the company's market capitalization is approximately $14.12 million, with a stock price of $1.50 per share.
Pipeline Development
BullFrog AI is advancing several therapeutic candidates:
- BF-222: A novel formulation of mebendazole in Phase I for glioblastoma treatment.
- BF-223: A novel prodrug of mebendazole in preclinical development for glioblastoma.
- BF-114: In the discovery phase, targeting obesity and chronic liver diseases.
- Modified HSV-1: In the discovery phase for colorectal cancer treatment.
The company holds licensing agreements with George Washington University for siRNA targeting Beta2-spectrin in treating hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Additionally, it has agreements with Johns Hopkins University for a mebendazole formulation aimed at glioblastoma and other cancers.
Technological Platform and Innovation
BullFrog AI's bfLEAP™ platform is a proprietary AI/ML analytical tool designed to analyze preclinical and clinical data for biotechnology and pharmaceutical companies. The platform supports applications such as early target identification, mechanism-of-action elucidation, patient stratification, drug repurposing, and clinical trial optimization. Delivered through an intuitive, visual, and disease-centric interface, bfLEAP™ empowers researchers to make informed, strategic decisions efficiently.
Leadership Team
- Vininder Singh: Founder, Chairman, and Chief Executive Officer.
- Joshua Blacher, CPA, M.B.A.: Chief Financial Officer.
- J.T. Koffenberger: Chief Information Officer.
- Dr. Cetin Savkli, Ph.D.: Chief AI Advisor and Member of Advisory Board.
- Dr. David P. Recker, FACP, FACR, M.D.: Chief Medical Officer.
- Dr. Praveen Kudithipudi, M.B.A., M.D.: Chief Business Development Officer.
Competitor Profile
The health information services industry is experiencing significant growth, driven by advancements in AI and ML technologies. Key competitors include:
- Veeva Systems (VEEV): Provides cloud-based software for the global life sciences industry.
- Doximity (DOCS): Operates a professional network for physicians.
- Hims & Hers Health (HIMS): Offers telehealth services and personalized health products.
- Tempus AI (TEM): Specializes in AI-driven precision medicine solutions.
These companies focus on integrating technology into healthcare to improve patient outcomes and streamline operations.
Strategic Collaborations and Partnerships
In June 2025, BullFrog AI announced a strategic collaboration with Sygnature Discovery, a UK-based contract research organization specializing in drug discovery. This partnership aims to introduce BullFrog Data Networks™ to Sygnature's global biopharma clients, potentially generating between $15-$30 million in revenue for BullFrog AI through 2028.
Operational Insights
BullFrog AI's integration of AI/ML into drug development positions it uniquely in the biopharmaceutical industry. The company's proprietary technologies and strategic partnerships enhance its competitive advantage, enabling it to offer innovative solutions that address unmet needs in drug development and patient care.
Strategic Opportunities and Future Directions
BullFrog AI is poised to expand its technological capabilities and therapeutic pipeline. The company plans to leverage its bfLEAP™ platform to identify new therapeutic targets and optimize clinical trials. Strategic collaborations, such as the partnership with Sygnature Discovery, are expected to enhance market reach and revenue streams. By focusing on AI-driven solutions, BullFrog AI aims to address critical challenges in drug development and improve patient outcomes.
Contact Information
- Website: www.bullfrogai.com
- LinkedIn: BullFrog AI
This profile provides a comprehensive overview of BullFrog AI Holdings, Inc., highlighting its strategic initiatives, technological innovations, and market positioning within the biopharmaceutical industry.
